Sign Out
Usually for adults, 2.5 mg as luseogliflozin should be orally administered once daily before or after breakfast. When the effect is insufficient, the dose can be increased to 5 mg once daily while closely monitoring the clinical course.
Patients with Renal Impairment: Patients with severe renal impairment or patients with end-stage renal failure being treated by dialysis (eGFR: 15 mL/min/1.73m2 to 29 mL/min/1.73m2): Lusefi should not be administered, because it is not expected to be effective in these patients.
Patients with moderate renal impairment (eGFR: 30 mL/min/1.73m2 to 59 mL/min/1.73m2): The necessity of administration should be carefully considered, because Lusefi may not be sufficiently effective.
Patients with Hepatic Impairment: No dosage adjustment is necessary for patients with mild or moderate hepatic impairment.
Elderly: Because physiological function is generally impaired in elderly patients, Lusefi should be administered carefully while monitoring the conditions of patients.
Because detection of the symptoms of dehydration (including thirst) may be delayed in elderly patients, caution should be exercised.
Pediatric Population: The safety and efficacy of luseogliflozin in children aged 0 to < 20 years have not yet been established. No data are available.
Continue with Google